Advances in Cancer Biomarkers

From biochemistry to clinic for a critical revision

  • Roberto Scatena

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 867)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Generality

  3. Tumor Markers – A Critical Revision: Enzymes

    1. Front Matter
      Pages 91-91
    2. J. W. Salman, I. G. Schoots, S. V. Carlsson, G. Jenster, M. J. Roobol
      Pages 93-114
    3. Vladimir Jurisic, Sandra Radenkovic, Gordana Konjevic
      Pages 115-124
    4. Maria Antonietta Isgrò, Patrizia Bottoni, Roberto Scatena
      Pages 125-143
  4. Tumor Markers – A Critical Revision: Hormones

    1. Front Matter
      Pages 157-157
  5. Tumor Markers – A Critical Revision: Oncofetal Proteins

    1. Front Matter
      Pages 177-177
    2. Dave Li, Shinji Satomura
      Pages 179-193
  6. Tumor Markers – A Critical Revision: Cytokeratins

    1. Front Matter
      Pages 195-195
    2. Andrea Nicolini, Paola Ferrari, Giuseppe Rossi
      Pages 197-225
  7. Tumor Markers – A Critical Revision: Carbohydrate Markers

    1. Front Matter
      Pages 227-227
    2. Patrizia Bottoni, Roberto Scatena
      Pages 229-244
  8. Tumor Markers – A Critical Revision: Blood Group Antigens

    1. Front Matter
      Pages 245-245
    2. Salvatore Scarà, Patrizia Bottoni, Roberto Scatena
      Pages 247-260
  9. Tumor Markers – A Critical Revision: Genetic Markers

    1. Front Matter
      Pages 261-261
    2. Kim De Leeneer, Kathleen Claes
      Pages 263-275
    3. Marianne Schmid, Jens Hansen, Felix K.-H. Chun
      Pages 277-289
  10. Tumor Markers – A Critical Revision: Various Protein Markers

    1. Front Matter
      Pages 291-291
    2. Patrizia Bottoni, Teresa De Michele, Roberto Scatena
      Pages 317-323
  11. Receptors as Biomarkers

  12. Perspectives

    1. Front Matter
      Pages 339-339
    2. Evi S. Lianidou, Athina Markou, Areti Strati
      Pages 341-367
  13. Back Matter
    Pages 369-372

About this book


At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes.  Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply  monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely  know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and “polluted” knowledge may have dramatic consequences for patient.  The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology.

This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.


biomarkers cancer diagnosis cancer pathophysiology cancer therapy metastasis

Editors and affiliations

  • Roberto Scatena
    • 1
  1. 1.Institute of Biochemistry and Clinical BCatholic University School of MedicineRomeItaly

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods